CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the completion of its business combinat…
Author: Business Wire
NovaBay CEO Issues Letter to Stockholders
EMERYVILLE, Calif.–(BUSINESS WIRE)—- $NBY #Avenova–NovaBay announces Avenova and CelleRx Clinical Reset to be available in brick-and-mortar stores.
National Vision Appoints Jose Armario to Board of Directors
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, today announced the appointment of Jose Armario, chief executive officer and p…
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
Eye Health America Acquires Three Optometric Practices in the Pee Dee Region of South Carolina: First Vision Group, Marlboro Eye Care Associates and Vision Care
GREENVILLE, S.C.–(BUSINESS WIRE)–Today, Eye Health America (EHA), a leading eye care practice management organization in the Southeast, welcomes three established optometric practices into its business family: David Hamill, OD and First Vision Group …
Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Design
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
Global Antiglaucoma Drugs Market Report 2020: $10.76 Billion Opportunities and Strategies to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Antiglaucoma Drugs Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering. This report describes and evaluates the global antiglaucoma d…
Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release four…
GenSight Biologics annonce la publication dans Communications Biology de la preuve de concept pour GS030-Drug Product chez le singe
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le tr…
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
NEW YORK–(BUSINESS WIRE)–Horizon Therapeutics expands partnership with Medidata to speed clinical trial start-up and completion, using a broad range of technology solutions.
$13.4 Billion Contact Lense Markets – Global Forecasts to 2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Contact Lense Market – Forecasts from 2020 to 2025” report has been added to ResearchAndMarkets.com’s offering. The contact lenses market is evaluated at US$9.461 billion for the year 2019 growing at a CAGR of 5.98% reachi…
NeuroVision Imaging Inc., Announces New Funding From the ADDF to Develop Affordable, Accessible Biomarkers to Diagnose Alzheimer’s and Related Dementias
SACRAMENTO, Calif.–(BUSINESS WIRE)–NeuroVision Imaging Inc., announces new funding From the ADDF to develop affordable, accessible biomarkers to diagnose Alzheimer’s and other dementias
Global Synoptophore Market (2020 to 2026) – by Application, Type, End-user and Region – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Synoptophore Market By Application (Diagnostic and Therapeutic), By Type (Manual and Automated), By End-user (Clinics, Hospitals and Other End-users), By Region, Industry Analysis and Forecast, 2020 – 2026” report h…
Shift Admin, Part of QGenda, Named 2021 Best in KLAS for Physician Scheduling Category
ATLANTA–(BUSINESS WIRE)– #BestinKLAS–QGenda, the leading innovator in enterprise healthcare workforce management solutions, today announced Shift Admin, part of QGenda, was named the top ranking solution for Physician Scheduling in the 2021 Best in …
Inflammasome Therapeutics Says Study Published Today in Proceedings of the National Academy of Sciences Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMD
NEWTON, Mass.–(BUSINESS WIRE)– #InflammasomeTherapeutics–Study published today provides human data confirming potential of Inflammasome Therapeutics’ Kamuvudines for prevention of Dry AMD
Mati Therapeutics Announces Purchase of Rights From Novelion Therapeutics Inc.
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that it has purchased all rights related to Mati’s Evolute Punctal Plug Delivery System (PPDS) from Novelion Therapeutics Inc. (“Novelion”). This purchase is part of Novelion’s v…
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
DUBLIN & GAITHERSBURG, Md.–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstan…
Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined AMD, today announced the commencement of a Phase 2a trial advancing GEM103 as a potential add-o…
LENSAR Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O’Farrell
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq:LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced the expansion of its Board of Di…